CHUANG, WAN LONG,庄万龙,莊萬龍,YU, MING LUNG,余明隆,余明隆,DAI, CHIA YEN,戴嘉言,戴嘉言,HUANG, JEE FU,黄志富,黃志富,LU, MING YING,吕明颖,呂明穎,HSI, EDWARD,眭 致远,眭 致遠
申请号：
TW105138879
公开号：
TW201827601A
申请日:
2016.11.25
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.本發明提供一種預測長效型干擾素合併雷巴威林之療效於罹患慢性C型肝炎個體的方法,包括:(a)在長效型干擾素合併雷巴威林治療一週後,檢測該個體血液樣品中基因的表現量,基因包括RSAD2、LOC26010、HERC5、HERC6、IFI44、SERPING1、IFITM3和DDX60;及(b)根據該基因表現量的累積倍數變化計算一基因分數,當該基因分數等於或高於一臨界值時,該方法預測長效型干擾素合併雷巴威林可成功治療該個體的慢性C型肝炎。
